Efficacy and Safety of Interferon Beta-1b in the Management of Patients with COVID-19: A Prospective, Open-Label, Non-Randomized Trial
Backgrounds: There is no proven therapy for coronavirus disease 2019 (COVID-19) so far. The aim of this study was to evaluate the effect of interferon beta-1b combined with lopinavir/ritonavir and hydroxychloroquine in managing COVID-19.Methods: This is a non-randomized, open-label study on adult pa...
Saved in:
Main Authors: | Nima Rouhani (Author), Elahe Karimpour-razkenari (Author), Mostafa Alizadeh Forutan (Author), Monireh Ghazaeian (Author), Ebrahim Salehifar (Author), Mohammad Sadegh Rezai (Author), Sahar Fallah (Author) |
---|---|
Format: | Book |
Published: |
Research Center for Rational Use of Drugs (RCRUD),
2021-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluating the Effects of Clinical Characteristics and Therapeutic Regimens on Mortality in Hospitalized Patients with Severe COVID-19
by: Elahe Karimpour-Razkenari, et al.
Published: (2022) -
Clinical Characteristics of Intravenous Pantoprazole Consumption in Cardiac Intensive Care Unit
by: Gohar Eslami, et al.
Published: (2021) -
The Pattern of Morphine Necessity for Acute Renal Colic Patients in the Emergency Department; A Cross-Sectional Observational Prospective Study
by: Elahe Karimpour-Razkenari, et al.
Published: (2023) -
Successful treatment of invasive mycobacterium infection with interferon beta in a patient with Interferon-Gamma Receptor 1 deficiency
by: Fayhan Alroqi, et al.
Published: (2024) -
No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study
by: Yin-Qiu Huang, et al.
Published: (2020)